NCT01037504 - AZD5423 Multiple Ascending Dose Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Healthy

Interventions

DRUG

AZD5423

Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

DRUG

Placebo

Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.

Trial Locations (1)

Unknown

Research Site, London Bridge